visual abstract to accompany article

🚨 Editor’s Choice 🚨
"Cellular and humoral immunogenicity of respiratory syncytial virus vaccination in solid organ transplant recipients," by Bronder et al
doi.org/10.1016/j.aj...
#OpenAccess #Immunogenicity #RSV #SolidOrganTransplantation
@martinasester.bsky.social @uni-saarland.de.bsky.social

To our knowledge, this is the 1st placebo-controlled human clinical trial demonstrating a fungal adjunct enhancing vaccine response.
#Immunogenicity increased. #Reactogenicity decreased.

🍄Fungal #mycelium, ancient organisms w/ deep evolutionary intelligence, may offer a scalable, affordable...

3/5

mRNA vaccination facilitates the prevention and control of infectious diseases at an unprecedented speed

This review discusses the feasibility of #mRNAVaccines in the prevention & control of #InfectiousDiseases and the factors that enhance their #Immunogenicity, highlighting the critical role of antigenic design, challenges and future perspectives.

#OpenAccess: doi.org/10.1016/j.dc...

Review article from Cameron Rostron et al., Molecular and Inflammatory Etiologies of β-Cell
Dysfunction in Type 1 Diabetes
🖱️ https://ow.ly/c15F50XMMxO
#BetaCell #Immunogenicity

Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis Background: Adalimumab, a monoclonal antibody targeting TNFα, treats autoimmune diseases but induces anti-drug antibodies in 30–60% of patients, reducing its efficacy. Objective: This study investigates molecular mimicry as a mechanism behind this immunogenicity, where bacterial immunoglobulin domains structurally resemble adalimumab’s light chain, triggering immune responses. Methods: Using PSI-BLASTp and IBIVU Praline, there are 40 bacterial antigens homologous to adalimumab, with eight clinically relevant strains. Results: Structural analysis revealed 94% amino acid identity between the immunoglobulin domain of Escherichia coli strain B1 and adalimumab’s light chain, and 89.67% similarity with Corynebacterium pyruviciproducens. Root Mean Square Deviation values confirmed strong structural homology. Additionally, five cross-reactive B-cell epitopes were predicted, suggesting overlapping surfaces that may promote immune cross-reactivity and anti-drug antibody development. Conclusions: These findings emphasize the role of bacterial immunoglobulin domains in adalimumab immunogenicity and highlight further need for experimental validation and improved strategies to reduce immune responses in biological therapies.

Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis #Adalimumab #Immunogenicity #AutoimmuneDiseases #BiologicTherapy #MolecularMimicry

Reviewing the tissue distribution, transfection rates and #Immunogenicity of recombinant adeno-associated virus serotype 8 (#AAV8) in gene therapy, with insights into the applications and challenges of using AAV8 as a vector.

#OpenAccess: doi.org/10.1016/j.ge...

This phase Ib/IIa study evaluating the safety, #Pharmacokinetics, #Pharmacodynamics, #Immunogenicity & preliminary efficacy of CM313, an anti-CD38 antibody, in SLE patients showed manageable safety & encouraging clinical efficacy. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

A New Vaccine Candidate Strain of Coxsackievirus B5 Selected on the Basis of its Biological Properties - Zoonoses Journal KM299-L05 strain has potential as a novel CVB5 vaccine candidate in China

An inactivated CVB5 #Vaccine (derived from KM299-L05 strain) produced #NeutralizingAntibodies with high titers against various clinical CVB5 isolates, demonstrating #Immunogenicity & immunoprotection, & providing a platform for developing multivalent CVB vaccines.

#OpenAccess: tinyurl.com/27whq3oa

EpiVax Appoints Dr. Vibha Jawa as Chief Scientific Officer to Drive Scientific Strategy EpiVax has announced the appointment of Dr. Vibha Jawa as Chief Scientific Officer, succeeding founder Annie De Groot. Dr. Jawa brings over 20 years of expertise in biopharmaceuticals.

EpiVax Appoints Dr. Vibha Jawa as Chief Scientific Officer to Drive Scientific Strategy #USA #Providence #EpiVax #Immunogenicity #Vibha_Jawa

EpiVax Appoints Dr. Vibha Jawa as New Chief Scientific Officer to Lead Scientific Strategy EpiVax, a leader in preclinical immunogenicity assessment, announces the appointment of Dr. Vibha Jawa as CSO, succeeding Dr. Annie De Groot.

EpiVax Appoints Dr. Vibha Jawa as New Chief Scientific Officer to Lead Scientific Strategy #United_States #Providence #EpiVax #Immunogenicity #Dr._Vibha_Jawa

EpiVax Appoints Dr. Vibha Jawa as Chief Scientific Officer, Promising Innovative Advancements EpiVax has appointed Dr. Vibha Jawa as its new Chief Scientific Officer. With over 20 years in biotech, she will lead advancements in immunogenicity.

EpiVax Appoints Dr. Vibha Jawa as Chief Scientific Officer, Promising Innovative Advancements #USA #Providence #EpiVax #Immunogenicity #Vibha_Jawa

EpiVax Welcomes Dr. Vibha Jawa as the New Chief Scientific Officer to Enhance Scientific Strategy EpiVax announces the appointment of Dr. Vibha Jawa as Chief Scientific Officer, aiming to further their mission in immunogenicity assessment and biologic therapeutics.

EpiVax Welcomes Dr. Vibha Jawa as the New Chief Scientific Officer to Enhance Scientific Strategy #USA #Providence #EpiVax #Immunogenicity #Vibha_Jawa

EpiVax Welcomes Dr. Vibha Jawa as Chief Scientific Officer to Propel Innovation EpiVax appoints Dr. Vibha Jawa as Chief Scientific Officer, marking a pivotal leadership transition aimed at advancing immunogenicity assessment in biologics.

EpiVax Welcomes Dr. Vibha Jawa as Chief Scientific Officer to Propel Innovation #USA #Providence #EpiVax #Immunogenicity #Vibha_Jawa

Our CSO, Erik Procko, is speaking at PEGS Boston! Join him 5/13 at 5:10pm ET for his talk: A Library-Based Approach for Mapping and Engineering HLA-II Epitope Landscapes. #PEGSBoston #AI #ML #Biotech #Immunogenicity #CyrusBio
tinyurl.com/mr2v3hxa

🦠 New work by Rubinson clarifies the poor #immunogenicity of the capsular polysaccharide α2 → 8 polysialic acid of N. meningitidis and E. coli by providing a #SolutionStructure

➡️ doi.org/10.1002/1873-3468.70032

#MeningococcalDisease #SupramolecularStructures

The next talk is by Caroline Chisenga from Zambia 🇿🇲 who is telling us about her work on #cholera vaccines and their #immunogenicity @sangerinstitute.bsky.social #IFR2025

Effect of Inactivated Vaccines Against SARS-CoV-2 on Immunogenicity Outcome | Disaster Medicine and Public Health Preparedness | Cambridge Core Effect of Inactivated Vaccines Against SARS-CoV-2 on Immunogenicity Outcome - Volume 19

www.cambridge.org/core/journal...

#publichealth #vaccines #sarcov2 #immunogenicity

Systems-level immunomonitoring in children with solid tumors to enable precision medicine In a population-based cohort of 191 children with diverse solid tumors, systems-level analyses unravel immune variation with age and tumor type and provide a reference for future precision immunothera...

#Paediatrics | #Cancer | #ImmuneSystem | #Immunotherapy |

Yet Another Phenomenal Resource from @petterbrodin.bsky.social & Friends |

Breaking OPEN ACCESS Study Online at @cellpress.bsky.social |

#immunogenicity | #Tcells | #inflammation |

For the future, the model opens up plenty of novel opportunities for #Immunology research, e. g, #vaccine development and #immunogenicity evaluation.

EpiVax: Leading Innovation in Immunogenicity Risk Assessment for 2024 EpiVax showcases significant advancements in immunogenicity risk assessment for biological therapies in 2024 with innovative services and remarkable growth.

EpiVax: Leading Innovation in Immunogenicity Risk Assessment for 2024 #EpiVax #Immunogenicity #Biological_Therapies

EpiVax Celebrates Remarkable Innovations in Immunogenicity for 2024 This article reviews EpiVax's key innovations and growth in immunogenicity assessment throughout 2024, showcasing new services and significant advancements.

EpiVax Celebrates Remarkable Innovations in Immunogenicity for 2024 #USA #biotechnology #Providence #EpiVax #Immunogenicity

Pfizer, BioNTech’s Mixed Phase III Data Sets Back COVID-19-Flu Vaccine Candidate The companies’ late-stage stumble could allow Moderna to widen its lead, with its mRNA-based combination vaccine eliciting superior immune responses against COVID-19 and three influenza strains.

Pfizer & BioNTech’s #mRNA combo #vaccine met only 1 primary #immunogenicity endpoints

could be a boon for #Moderna
which is also working on a #COVID-19-Fflu #combo-vaccine

Moderna combo vaccine #mRNA-1083 induced significantly #stronger #immune #responses against #SARS-CoV-2 & 3 #Flu virus strains